SCHEMBL3860011

SCHEMBL3860011

COc1cccc(C(=O)Nc2ccccn2)n1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.57
RAB9A P51151 6/20 0.57
SMN1; SMN2 Q16637 5/20 0.57
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
TP53 P04637 2/20 0.57
F2 P00734 1/20 0.57
GAA P10253 1/20 0.57
KDM4E B2RXH2 1/20 0.57
ALDH1A1 P00352 1/20 0.57
TSHR P16473 1/20 0.57
NFKB1 P19838 1/20 0.57
NFKB2 Q00653 1/20 0.57
RELA Q04206 1/20 0.57
GRM4 Q14833 2/20 0.55
CNR2 P34972 1/20 0.55
GRM5 P41594 4/20 0.54
MAPT P10636 1/20 0.51
PKM P14618 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3870512 0.81 GRM5 (0.74) NPC1RAB9ASMN1; SMN2TP53KDM4E
SCHEMBL31277543 0.81 GRM5 (0.65) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL3859292 0.81 GRM5 (0.65) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL1381050 0.80 GRM5 (0.45) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL9384187 0.80 NPC1 (0.72) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL13313417 0.80 POLB (0.70) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL16996703 0.80 NPC1 (0.62) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL13715665 0.78 SMN1; SMN2 (0.60) NPC1RAB9ASMN1; SMN2TP53KDM4E
SCHEMBL3862923 0.76 CNR2 (0.79) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL16987767 0.76 BRD4 (0.51) NPC1RAB9ASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1715867-A4 BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2009-04-15 EP disclosed
US-20070149547-A1 Bipyridyl amides as modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME CORP. 2007-06-28 US disclosed
US-20070149547-A1 Bipyridyl amides as modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME CORP. 2007-06-28 US disclosed
US-20070149547-A1 Bipyridyl amides as modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME CORP. 2007-06-28 US disclosed
EP-1715867-A1 BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2006-11-02 EP disclosed
WO-2005079802-A1 BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2005-09-01 WO disclosed
WO-2005079802-A1 BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149547-A1 Bipyridyl amides as modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GABRA5 NPC1 3248/4885RAB9A 1748/4885SMN1; SMN2 3565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.